RT Journal Article
T1 Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors
A1 Chica-Parrado, María Rosario
A1 Godoy-Ortiz, Ana
A1 Jiménez, Begoña
A1 Ribelles, Nuria
A1 Barragan, Isabel
A1 Alba, Emilio
K1 Breast cancer
K1 Neoadjuvant chemotherapy
K1 Pathological complete response
K1 Predictive markers
K1 Residual disease
K1 Neoplasias de la mama
K1 Terapia neoadyuvante
K1 Trastuzumab
AB Neoadjuvant Chemotherapy (NAC) in Breast Cancer (BC) has proved useful for the reduction in tumor burden prior to surgery, allowing for a more extensive breast preservation and the eradication of subjacent micrometastases. However, the impact on prognosis is highly dependent on the establishment of Pathological Complete Response (pCR), in particular for Triple Negative (TN) and Hormonal Receptor negative/Human Epidermal growth factor Receptor 2 positive (HR-/HER2+) subtypes. Several pCR predictors, such as PAM50, Integrative Cluster (IntClust), mutations in PI3KCA, or the Trastuzumab Risk model (TRAR), are useful molecular tools for estimating response to treatment and are prognostic. Major evolution events during BC NAC that feature the Residual Disease (RD) are the loss of HR and HER2, which are prognostic of bad outcome, and stemness and immune depletion-related gene expression aberrations. This dynamic nature of the determinants of response to BC NAC, together with the extensive heterogeneity of BC, raises the need to discern the individual and subtype-specific determinants of resistance. Moreover, refining the current approaches for a comprehensive monitoring of tumor evolution during treatment, RD, and eventual recurrences is essential for identifying new actionable alterations and the integral best management of the disease.
PB MDPI
YR 2020
FD 2020-07-22
LK http://hdl.handle.net/10668/3761
UL http://hdl.handle.net/10668/3761
LA en
NO Chica-Parrado MR, Godoy-Ortiz A, Jiménez B, Ribelles N, Barragan I, Alba E. Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. Cancers. 2020 Jul 22;12(8):2012
DS RISalud
RD Apr 5, 2025